Schizophrenia Research Forum - A Catalyst for Creative Thinking
Home Profile Membership/Get Newsletter Log In Contact Us
 For Patients & Families
What's New
Recent Updates
SRF Papers
Current Papers
Search All Papers
Search Comments
News
Research News
Conference News
Plain English
Forums
Current Hypotheses
Idea Lab
Online Discussions
Virtual Conferences
Interviews
Resources
What We Know
SchizophreniaGene
Animal Models
Drugs in Trials
Research Tools
Grants
Jobs
Conferences
Journals
Community Calendar
General Information
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
History
SRF Team
Advisory Board
Support Us
How to Cite
Fan (E)Mail
The Schizophrenia Research Forum web site is sponsored by the Brain and Behavior Research Foundation and was created with funding from the U.S. National Institute of Mental Health.
In Search of Research Participants

Updated November 19, 2014

Seek research participants for studies. New posts will be featured in the "What's New" section of the website, and we'll also send them out in the SRF Newsletter. Please let us know if you have any success through this feature of the website.


Illuminate-301 Study

Antipsychotic medications are commonly used in patients with schizophrenia to treat acute psychosis and reduce the risk of future psychotic episodes. Atypical antipsychotics have been used in adults since the early 1990s and are associated with a lower rate of side effects such as muscular rigidity, tremors, and spasms compared with older antipsychotic medications. Lurasidone is an atypical antipsychotic medication that is currently used in adults in the US and Canada for the treatment of schizophrenia and is being investigated in this study for use in teenagers.

Children and adults differ in their basic biology and there is always a possibility that these two groups will react differently to a certain medication. It is therefore important to conduct clinical research studies to ensure medications intended for children are safe and effective in children. The goal of this study is to learn more about treating early-onset schizophrenia, and to potentially increase future treatment options for children with schizophrenia.

About the Illuminate-301 Study
The Illuminate-301 Study will last for up to 10 weeks. Participants will be asked to gradually stop taking some of the medications they are currently receiving, including any antipsychotic medications. If they are still eligible to join the study after this time, they will be randomly assigned to receive one of two doses of lurasidone or a placebo (which looks the same as the investigational medication but contains no actual medication) every day for six weeks.

Study participants have a two-in-three chance of receiving lurasidone and a one-in-three chance of receiving placebo. Both lurasidone and placebo will be given in the form of tablets. Study participants may be inpatients, outpatients, or partially hospitalized during the study. If the participant is an outpatient, they will be asked to come to the study center for visits approximately once a week, accompanied by a parent, legal guardian, or caregiver. The child's overall health will be monitored throughout the study with assessments including physical examinations and blood tests.

All study-related assessments and medication, including hospitalization if needed, will be provided at no cost.

After completing the six-week treatment phase of this study, participants may be eligible to participate in a separate two-year extension study where everyone will receive lurasidone.

Who can participate?

We would like to hear from the caregivers/families of teenagers who:

  • are 13 to 17 years of age;
  • have been diagnosed with schizophrenia;
  • have some active symptoms of schizophrenia that require treatment, such as believing or experiencing things that are not really true or having disorganized/unusual thoughts.

The study doctor will determine whether an individual is eligible for the study at the first study visit.

If you are interested in receiving more information about the study or discussing any of the details in this letter, please contact me using the details below.

Robert Findling, MD, MBA
Principal Investigator
The Illuminate-301 Study Team
Kennedy Krieger Institute Clinical Trial Unit
443-923-3850 or Researchtrials@kennedykrieger.org
www.SchizophreniaClinicalResearch.com
JHM IRB No.-NA_00092723
ClinicalTrials.gov NCT01911429
Study Sponsor: Sunovion Pharmaceutical


A Research Study for Efficacy and Safety of NaBen (Sodium Benzoate) for Symptoms of Schizophrenia in Adolescents

The purpose of this research study is to evaluate the safety effectiveness of NaBen (sodium benzoate), compared with placebo, in male and female adolescents, ages 12 to 16 years, with schizophrenia.

The first part of the research study involves a telephone interview and a screening period to determine if the adolescent is eligible to participate in the research study. During screening we will evaluate participants using medical, biological, behavioral, and developmental measures including behavioral assessments, physical examinations, blood draws, vital signs, ECGs, urine drug screen, and pregnancy testing for females.

The most common risks of this study drug include a loss in appetite and vomiting. Some participants may also find medical procedures such as blood draws, electrocardiogram (ECG), urine testing and physical examinations upsetting or uncomfortable.

Individuals who are eligible to participate may continue on to the treatment phase of the research study (which includes up to seven visits over a 10-week period; each study visit lasting approximately two to three hours). During the treatment phase, participants will receive NaBen (sodium benzoate) or a placebo (a tablet containing no active drug but looks like NaBen). Assignment to the NaBen (sodium benzoate) or placebo study group will be decided by chance, similar to flipping a coin. There will be a reimbursement ($65.00) for time and travel for each completed study visit.

If you have any questions about this research study, please feel free to contact Kara Fultz (study coordinator) at 443-923-9191 (fultz@kennedykrieger.org) or myself at 443-614-3225 (Rfindli1@jhmi.edu). As you know, schizophrenia research is critical to furthering our understanding of this disability that affects so many children and families. Together, we may be able to find better treatments to improve the lives of individuals living with schizophrenia. This research study is sponsored by SyneuRx International Corporation.

For more information, please contact:

Robert Findling, M.D., M.B.A.
Professor of Psychiatry and Behavioral Science
Johns Hopkins University
Bloomberg Children's Center
1800 Orleans Street, Suite 12344A,
Baltimore, MD 21287
443-614-3225
Rfindli1@jhmi.edu
JHM-IRB No. IRB00030540
ClinicalTrials.gov No. NCT01908192


Study on Antipsychotic Medications and Their Side Effects

Researchers at the University of Michigan are conducting a study on antipsychotic medications and their side effects, and are recruiting participants:

Eligibility:

  • Be age 18-90
  • Have a diagnosis of schizophrenia or a similar disorder (e.g., schizoaffective, schizophreniform
  • Have been taking antipsychotic medication (e.g., Zyprexa, Geodon, Abilify, Seroquel, Invega, Latuda, Clozaril, Saphris, Fanapt, Solian) for six months at least

The study takes three to four hours and consists of the following:

  • An interview discussing psychiatric & medical history, thoughts, functioning, diet, smoking, and activities
  • A blood draw (for hormone, chemical, and genetic analysis)
  • Body measurements (e.g., weight, height)
  • Blood vessel functioning measurement
  • Two follow-up phone calls

Compensation: $80 in cash upon completion of the entire study

Location: Michigan Clinical Research Unit (MCRU) at the University of Michigan Health System in Ann Arbor, MI

Transportation can be provided at no cost if you live in the Ann Arbor/Ypsilanti area or neighboring areas.

Note: Should you qualify, NO change will be made to your current treatment.

For more information, contact:

Zarina Kraal, M.S.
Phone: (734) 358-2136
Email: sczresearch@umich.edu


New Study on Genetic Cause of Schizophrenia: Research Team at VA Boston Healthcare System Uses Latest Technologies in Human DNA Analysis

According to the National Institute of Mental Health, approximately 2.4 million American adults have schizophrenia, or 1.1 percent of the U.S. population over the age of 18. Mental health experts say schizophrenia has long been known to run in families.

To address this gap in knowledge, a research team at the VA Boston Healthcare System in Brockton, Massachusetts, is conducting a study using the latest technologies in human DNA analysis to help determine the specific gene or sequence of genes causing this severe psychiatric disorder. The study is recruiting volunteers from families where multiple members have been diagnosed with schizophrenia or related disorders. Participation is not limited to veterans, but is open to the general public.

The study is supported by a grant from Amgen, a leader in the development of therapeutic products from genetic research that address major diseases worldwide.

For more information, contact Paul Nelson, M.Ed., Research Coordinator, at GeneticsResearchVA@gmail.com.

Paul Nelson, M.Ed.
Clinical Research Coordinator
Boston VA Research Institute
VA Boston Healthcare System
940 Belmont St., Bldg. 5, #B211C
Brockton, MA 02301
774-826-1131 office
845-981-9514 cell


VA Boston Healthcare System and Amgen Searching for Candidate Genetic Defects for Schizophrenia Using the Latest Genetic Technology

Research Study Volunteers Needed!

Volunteers
We are looking for families with THREE or more members diagnosed with schizophrenia or related disorders to participate in this research study. We are interested in interviewing the individuals who have been diagnosed with schizophrenia as well as several healthy family members.

Purpose
The purpose of this study is to learn more about the role of genes in causing schizophrenia.

Involvement
Structured clinical interview, neurological testing, and a blood draw. Study participation may take one or two visits, but we will work with your schedule.

Locations
The study will take place at the Brockton or Jamaica Plain Veterans Affairs Hospital in Massachusetts. We will assist with travel when possible. If these locations are not convenient, home visits are also an option.

Compensation
You may receive $130 upon completion of this study.

Contact
To learn more about this study or volunteer to participate, please contact us and we will be happy to answer any questions!

Paul Nelson, M.Ed.
Study Coordinator
Email GeneticsResearchVA@gmail.com or call (845) 981-9514

Please include name, age and preferred method of contact.

Lynn E. DeLisi MD
Study Investigator

See Study Flyer


Examining the Relationship Between Traumatic Brain Injury and the Onset of Schizophrenia-Like Symptoms: A Case Control Study

This study will examine the neuropsychological test findings in seven TBI victims with a subsequent presentation of schizophrenia-like symptoms and no history of psychosis to identify the neuropsychological pattern and profiles in terms of relative strengths and weaknesses in each cognitive domain.

The study will examine the hypothesis that unique neuropsychological profiles will emerge for those patients with TBI and a subsequent diagnosis of schizophrenia compared to those who have a diagnosis of schizophrenia and no history of TBI. The sample will comprise seven participants. The group will comprise individuals who appear to have a schizophrenia-like presentation and a verifiable TBI. Each participant will undergo a neuropsychological evaluation comprising a number of different neuropsychological and personality assessments. The current study will examine the neuropsychological test findings in seven TBI victims with a subsequent presentation of schizophrenia-like symptoms and no history of psychosis to identify the neuropsychological pattern and profiles in terms of relative strengths and weaknesses in each cognitive domain. The study will examine the unique potential neuropsychological profiles that may emerge for those patients with TBI and a subsequent diagnosis of schizophrenia compared to those who have a diagnosis of schizophrenia and no history of TBI.

Click here to take the survey.

If interested, please contact Denise Romanow, Illinois School of Professional Psychology.


Participate in Research: Living With Schizophrenia in the Family
My name is Rachel Morton from the School of Psychology and Counselling at the Queensland University of Technology. I'm researching the experience of family members who have lived with or are living with a close family member who has been diagnosed with schizophrenia. I would like to know what you do to cope with stress, your own personal characteristics, including some questions about your medical history, your levels of stress, and any potential benefits.

If you'd like to help me in this study, I'm looking for parents, children, and siblings (aged 16 and older) who have lived with their relative at some point since he or she was diagnosed to complete an online questionnaire package. Your participation is expected to take 20-25 minutes. Please view the attached recruitment flyer for further details on the study and how to participate. This study has been approved by the QUT Human Research Ethics Committee (approval number 1100001107).

Click on this link to be taken to the questionnaire.

To recognize your contribution, you are able to enter into a draw to receive one of two $50 shopping vouchers.

Please pass this on to any other family members or friends who may be eligible to participate.

Your interest is greatly appreciated.

Rachel Morton
Professional Doctorate Candidate
School of Psychology and Counselling
Queensland University of Technology
E-mail: rd.morton@connect.qut.edu.au


Schizophrenia Symptoms Study at UC Berkeley
Our research at UC Berkeley is trying to come up with ways to better recognize schizophrenia symptoms so we can then develop treatments that are better able to provide some relief. In our research, we use clinical interviews to get a first hand account of a person's symptoms and how they impact daily life.

What will take place?

  • The study involves two visits, each lasting about 2 hours. You will participate in an interview, see some pictures and answer some questions about them, tell us about past memories and think about these experiences in the future, we will measure your facial muscle movement using sensors, and you will complete some computer and paper-and-pencil measures.
  • Reimbursed $15 per hour for both visits
  • Takes place on the UC Berkeley campus

Who can participate?

  • Between 18 and 65 years old
  • Diagnosis of Schizophrenia or Schizoaffective Disorder
  • Speak fluent English
  • No neurological disease or head injury
  • No current depression, drug or alcohol abuse

To schedule a time to participate, please contact:

Emotion and Social Interaction Lab
Department of Psychology, UC Berkeley
510-643-4098
E-mail: ucbsymptomsstudy@gmail.com

Or for more information visit www.mentalhealthresearch.berkeley.edu/schizophrenia/.

If you know of any men or women with schizophrenia or schizoaffective disorder that might be interested and able to participate in our study, please tell them about our study.


Are You or a Family Member Being Treated for Schizophrenia?Posted 8 November 2011

The cognitive neurology/neuropsychology group at The Johns Hopkins University is conducting research to determine whether very mild electrical stimulation can improve attention, memory, and other cognitive abilities in adults with schizophrenia or their first-degree relatives.

Study participants will be asked to complete several cognitive tasks while receiving mild electrical stimulation through electrodes placed on the scalp. This technique is safe and completely painless. The study is approved by the Johns Hopkins Medicine Institutional Review Board.

The studies are being conducted at the Johns Hopkins Hospital and usually require two sessions. The first session lasts approximately two hours and the second session lasts about an hour. Compensation is provided for participation.

For more information please call Mark Varvaris at (410) 502-6345.


Do You or Your Family Member Have a Diagnosis of Schizophrenia, Schizoaffective Disorder, or Bipolar Disorder With Psychotic Features?Posted 30 September 2011

Researchers at Beth Israel Deaconess Medical Center in Boston, Massachusetts, are looking for participants for a mental health study. The purpose of this study is to explore various similarities and differences between people with and without bipolar or schizophrenia/schizoaffective disorder.

The B-SNIP study is looking for:

  • One person (aged 15-65) in a family willing to participate who has been diagnosed with either schizophrenia, schizoaffective or bipolar disorder with psychotic features.
  • Also, at least one first-degree relative (biological brother, sister, mother, father, or child). It does not matter whether these relatives have or do not have these illnesses.
  • Participants must not have a diagnosis of mental retardation, serious medical problems, or prolonged drug or alcohol abuse.

All procedures are painless and involve completing various testing measures, interviews, and questionnaires.

Participants can earn up to $200 for completion of the study, which typically lasts eight to 10 hours.

For more information about the B-SNIP study, contact Corin at 617-998-5016 or cpilo@bidmc.harvard.edu.


Experiences With Cannabis, Aspects of Personality and Liability to Psychological DisorderPosted 6 September 2011

We at Manchester Metropolitan University (England) have been researching the relationship between cannabis and psychosis for several years. We are currently looking for volunteers to assist us in our latest research project by answering a series of questions. We are looking for people over the age of 18, who have used cannabis at least once (whether you are a past or current user) and have a history of mental health problems. The questions should only take around 20 minutes and can be answered completely anonymously online via our website. If you would like to help or would like further information about our research, then please go to our website, or if you are based in the U.K., we can arrange for a pack containing information and paper copies of the questionnaires to be sent to you. To request an information pack, you can phone +44 (0)161 247 2415 (if there is no response, then please leave a message), or you can write to

Rohan Morris
RIHSC/Department of Psychology
Elizabeth Gaskell Campus
Manchester Metropolitan University
Hathersage Road
Manchester
M13 0JA
England


Volunteers Needed for a Research Study on Cognitive FlexibilityPosted 9 June 2011

This study is run by investigators in the UCLA Department of Psychiatry at the Semel Institute. The goal of our research is to examine flexible thinking in healthy people who do and do not have a relative with a psychiatric disorder. Participation involves filling out several questionnaires and taking computer tests done on the Internet (from home!!). It involves less than 75 minutes of testing in total. Participation gives you chances to win raffle prizes. You must be between the ages of 18-55 to participate.

Interested?

For more information, please visit our website or contact: Dr. Fred Sabb at


Biological Prediction of Psychosis Susceptibility Among Adolescent Cannabis UsersPosted 22 April 2011

Study sites include:

The Brockton VA
940 Belmont St
Brockton MA, 02103

Corrigan Mental Health Center
49 Hillside St
Fall River, MA 02720

Beth Israel Deaconess Medical Center
330 Brookline Ave
Boston, MA 02215

This is a genetics study trying to determine whether or not using cannabis during adolescence increases the chances of developing psychosis later in life for individuals with a family history of psychiatric illness.

The study involves an interview with the participant, a brief phone interview with the participant's family member, an optional blood draw, and an 18-month follow-up interview.

Participants and family members are compensated for their time.

Contact information of PI and/or study team
Ashley Proal, Study Coordinator: 845-981-9514
Dr. Lynn DeLisi, PI: 774-826-3155

Study participant enrollment criteria
We are looking for individuals who

  • are ages 18-40;
  • have been diagnosed with schizophrenia, schiozaffective disorder, or psychosis;
  • used cannabis during adolescence and no other drugs OR have not used any drugs at all.

NIMH Genetic Study of Schizophrenia: Shortage of Family Trios Hinders Scientific DiscoveryPosted 8 February 2011

The National Institute of Mental Health has been conducting a large genetic study designed to understand the neurobiology of schizophrenia by identifying susceptibility genes. In the course of the past 11 years, NIMH scientists have identified over 30 such genes that may be involved in the development of schizophrenia. Scientists are now working to understand which of these genetic variations represent the "major players" in brain development and which genes must interact before schizophrenia brain impairment develops.

The complex genetic architecture of schizophrenia is further complicated by ethnic or racial differences in research participants. Researchers rely on the genetic analyses of "FAMILY TRIOS" to clarify the role that genes play in schizophrenia. A "FAMILY TRIO," as defined by this study, is composed of the member diagnosed with schizophrenia or schizoaffective disorder and his or her parents. If one or both parents are unwilling or unable to participate, then one or more biological siblings can participate and complete the "TRIO." NIMH currently does not have enough "Family Trios" to clarify the preliminary findings.

NIMH has made it easy for family trios to participate. Families do not need to travel to NIMH. Confidential interviews can be done by telephone and blood can be drawn in the family members' home community. All participating family members receive study compensation.

Genomics has begun to improve the understanding of the biology of health and complex medical illnesses; this will change the practice of medicine. Researchers rely on families of those who have schizophrenia to participate in the genetic study to help ensure that those suffering from schizophrenia are not left out of these genomic discoveries that are already beginning to change the course of treatment for other diseases such as cancer, blood disorders, and other conditions.

For details, please contact the NIMH Schizophrenia Research Program at 1-888-674-6464 (TTY: 866-411-1010) or . NIMH is located in Bethesda, Maryland, and is part of the National Institutes of Health of the Department of Health and Human Services.


Have You Ever Had a Patient With Clozapine-Induced Agranulocytosis?Posted 2 February 2011

The National Institute of Mental Health has funded a study (led by Jeffrey Lieberman and Patrick Sullivan) to understand the genetic basis of clozapine-induced agranulocytosis. One goal of this research is to develop a predictive test to determine an individual's risk of developing agranulocytosis. This could eliminate the need for ongoing white blood cell monitoring in many patients.

Physicians with current or former patients who developed agranulocytosis or granulocytopenia (ANC <1,000) while taking clozapine are asked to help make their patients aware of this study. Physicians and patients will be compensated for their efforts. If you have a current or former patient who developed clozapine-induced agranulocytosis, then please contact:

Victoria Huan, M.D., (212) 543-6750, OR James Gangwisch, Ph.D., (212) 543-5577,


UCSF & UCD Research StudyPosted 11 October 2010

Volunteers Needed for Study

Does computer training help the symptoms of early schizophrenia?

You are eligible to participate if

1. You have a clinical diagnosis of schizophrenia, schizophreniform disorder or schizoaffective disorder;
2. Your first episode of schizophrenia symptoms began within the last 5 years;
3. You are in good general medical health;
4. You are doing well and have been on the same medication, or no medication, for at least four weeks;
5. You are between the ages of 14 and 30;
6. You live in or around the San Francisco Bay Area OR Sacramento;
7. You are fluent and proficient in the English language.

We are conducting this study to aid our understanding of whether or not specialized computer training helps young people with schizophrenia lessen their symptoms and improve their thinking. The procedures consist of interviews and questionnaires, computer and paper and pencil tests, brain imaging tests (optional) and blood tests (optional). You will be paid approximately $5 for every hour of computer training and $20 for each lab appointment, up to $1,040 total.

Participants should be available to spend 60 minutes per day, five days per week, for eight consecutive weeks either at a home computer with Internet access or at a computer at UCSF, SF VAMC (for adult subjects only) or UCD.

Interested? Know someone who might be?

Call us for more information
UC San Francisco: 415-476-7278
UC Davis: 916-734-0512

A confidential phone screen will be conducted to determine initial eligibility.

(If you are under 18 years of age, please have your parents call.)

Principal Investigator: Sophia Vinogradov, M.D.
UCD Principal Investigator: Cameron Carter, M.D.


UCSF & UCD Research StudyPosted 11 October 2010

Have you or someone you know experienced recent worrisome changes in thoughts and/or feelings? If so, maybe PART can help.

We are looking for individuals ages 14-25 who are experiencing recent changes in their thoughts, feelings, and behavior, such as:

  • unusual thoughts
  • suspiciousness
  • odd behavior
  • distorted or changed perception of sights or sounds
  • ideas of special identity or abilities

Other changes may also include:

  • reduced concentration
  • reduced energy
  • depressed mood
  • sleep disturbance
  • trouble with work or school
  • anxiety
  • irritability
  • withdrawal from family or friends

Individuals who are experiencing difficulty functioning and who have a parent or sibling with a psychotic illness, such as schizophrenia, are also encouraged to contact us. We are conducting this study to aid our understanding of whether or not specialized computer training helps young people who are at risk for development of a serious psychiatric disorder lessen their symptoms and improve their thinking. The procedures consist of interviews and questionnaires, computer and paper and pencil tests, brain imaging tests (optional) and blood tests (optional). You will be paid approximately $5 for every hour of computer training and $20 for each lab appointment, up to $1,040 total.

Participants should be available to spend 60 minutes per day, five days per week for eight consecutive weeks either with a computer at home or at UCSF, SF VAMC (for adults only) or UCD.

Interested? Know someone who might be?

Call us for more information
UC San Francisco: 415-476-7278
UC Davis: 916-734-0512

A confidential phone screen will be conducted to determine initial eligibility.

(If you are under 18 years of age, please have your parents call.)

Principal Investigator: Sophia Vinogradov, M.D.
UCD Principal Investigator: Cameron Carter, M.D.


Schizophrenia and Bipolar Disorder Family Genetic Research StudyPosted 29 March 2010

The Maryland Psychiatric Research Center at the University of Maryland School of Medicine is currently conducting a NIMH-funded study on the genetic causes of schizophrenia and bipolar disorder. The purpose of the study is to discover how genetic risk for these illnesses and their associated biological and behavioral traits is transmitted in families.

You may be eligible to participate in the study if you meet these conditions:

  • Age between 15-65 years;
  • Diagnosis of schizophrenia, schizoaffective disorder or bipolar disorder (with psychosis);
  • Have at least one biological first-degree relative, i.e., a sister, brother, mother or father willing to participate. The relative does not need to be diagnosed with a psychiatric disorder but it is okay if they are;
  • No serious medical, neuron-ophthalmological or neurological illness (e.g., cancer, seizure disorders, encephalopathy);
  • No current substance abuse (within past three months) or past history of substance dependence (within six months or extensive history);
  • No ferromagnetic objects lodged in the body.

Participation involves the following:

  • Clinical interviews to evaluate diagnosis and gather other personal information;
  • Neuropsychological tests to examine thinking abilities such as attention and memory;
  • Electroencephalography (EEG)/Sensory Gating tests to measure brain activity in response to sounds;
  • Eyetracking tests to measure eye movements and visual attention;
  • MRI to measure brain structures and function;
  • Blood sample for DNA (genetic) studies;
  • Urine sample to screen for drugs and pregnancy.

The total amount of time it takes to complete the study is approximately 14-16 hours. Transportation can be provided if needed. All participants will be compensated for their time.

For more details, call our clinical coordinators: Heather Verron at 410-402-6822 or Megan Henry at 410-402-6834.


Study of Internalized Stigma Among Family Members of People With Mental IllnessPosted 29 March 2010

Stigma can have serious negative effects on people with mental illness and their family members. We are a team of University of British Columbia mental illness researchers who have developed a new questionnaire to assess internalized stigma in close family members (parents, brothers, sisters, and children) of people with mental illness. We are looking for family members of people with schizophrenia, bipolar disorder, or schizoaffective disorder to complete the questionnaire to help us validate it. You can participate in the study whether or not you have a mental illness yourself, as long as you have an affected family member. Participating in the study involves a telephone interview and completing questionnaires at two different time points. There is no travel involved in this study. Participants can complete the questionnaires from home.

If you are a parent, brother, sister, or child of a person with mental illness and would like more information about participating, please contact Emily Morris at or 604-875-2000, ext.4733.


Participate in ResearchPosted 4 February 2010

The Division of Addiction Psychiatry is located at 317 George Street, Suite 105, New Brunswick, New Jersey. Our researchers are always looking for individuals to participate in our studies. Most studies will compensate you for your time.

Studies currently open to enrollment:

Nicotine Nasal Spray

Randomized, Double-Blind, Placebo-Controlled Trial of Nicotine Nasal Spray as an Aid for Smoking Cessation in Schizophrenia is a two-year, project designed to study the efficacy of NNS and behavioral intervention for smoking cessation in smokers with schizophrenia. If you smoke more than 10 cigarettes per day, you may qualify to participate in a study looking at the quit rate of subjects who receive NNS and behavioral intervention compared to the quit rate of the control group who will receive the placebo spray plus same behavioral intervention. Participants are paid $390 for their participation in the study, which takes about 15 weeks to complete. For further information, or to refer a patient, please contact Dr. Jill Williams at 732-235-4600 or at .

Nicotine Intake in Smokers with Schizophrenia

UMDNJ-Robert Wood Johnson Medical School, Department of Psychiatry is conducting a research study to see if there are differences in ways that different groups of people smoke cigarettes and their nicotine intake. This is not a quit smoking study. If you have schizophrenia or bipolar disorder, and are between ages of 18 and 70 and you smoke, you may qualify to participate in a study looking at cigarette puffing behavior. Subjects are paid $100 for participation in the study which takes about 2-3 days to complete. The principal study researcher is Jill Williams, M.D., of the UMDNJ-RWJMS Psychiatry Department and the UMDNJ-Tobacco Dependence Program, 317 George Street, Ste 105, New Brunswick, NJ 08901. For more information, call Dr. Williams at 732-235-4600.


Research Volunteers NeededPosted 15 January 2010

Males and females who are between the ages of 18 and 39, and who have been diagnosed with schizophrenia, may be eligible to participate in a research study looking at specific symptoms that some people with schizophrenia experience.

Study requirements:
14.5 hours of interviews, questionnaires, memory tests, MRI scan, and collection of blood sample, which will be done in over 4 days at Bellevue Hospital and NYU School of Medicine. Monetary compensation will be provided

For further information about the study and your eligibility, please call Sarah at 212-263-0735, or Taryn at 212-263-0855, or Nicole at 212-263-8107, at the New York University School of Medicine.


Volunteers Needed for Language and Risk for Schizophrenia StudyPosted 8 January 2010

Language and Risk for Schizophrenia (LNR) is an NIMH-funded study through Harvard Medical School seeking healthy volunteers who have close relatives with schizophrenia. The purpose of the study is to compare the brains of people who either have or do not have a family history of schizophrenia. The study procedures include an interview, blood draw, testing, and head MRI. The procedures may take place at the following locations: Boston, Massachusetts; Brockton, Massachusetts, or Fall River, Massachusetts, depending on the availability, and we will assist with travel when possible. You may be compensated $130 upon completion of the study and receive a free picture of your brain.

For more information or to participate, please contact the clinical coordinator Gul Jabbar MA, at (845) 981-9514 or e-mail . When leaving a message, please include your name, phone number, and the best time to reach you.


Volunteers Needed for ResearchPosted 24 January 2008
  • Have you been given the diagnosis of schizophrenia by a mental health professional?
  • Are you at least 18 years old?
  • Have you not experienced severe symptoms for at least 6 months?

Hello, my name is Nisha Fernandes; I'm an advanced graduate student at the California School of Professional Psychology, San Francisco, and I'm currently seeking volunteers for my research about the experience of self in schizophrenia.

I want to have a deep understanding of schizophrenia and its process so that I, and other clinicians, may eventually learn how to effectively treat this phenomenon. In order for me to truly understand the experience of self in schizophrenia, I wish to talk with individuals who have gone through this process.

Interested persons will be asked to participate in a brief phone interview to determine if my study is a good fit for you and if you meet criteria for my study. If you are eligible for my study, you will be invited to two confidential, individual interviews of up to 1.5 to 2 hours each at a mutually agreed upon location (my school, a park, coffee shop, etc.). Volunteers who share their experience with me by participating in my study may find that it helps develop their own understanding of what they went through. It can also feel good to know that you are doing something that may eventually help others who are going through and will go through similar experiences with schizophrenia. Also, as a thank you for participating in my study, I will give you $50 at the end of the second interview.

If you are interested in volunteering, or have any questions at all about my study, please e-mail me .

Your help is greatly appreciated.


Genetic Study of Agranulocytosis with ClozapinePosted 13 March 2007

We are seeking patients who developed agranulocytosis while being treated with clozapine (Clozaril, Fazaclo). Criteria for participation are

1. patient is age 18 or over;

2. patient was diagnosed with agranulocytosis (ANC <500 mm) or granulocytopenia (ANC <1,000 mm) during treatment with clozapine;

3. patient was discontinued from clozapine treatment at time of the occurrence of the agranulocytosis or granulocytopenia;

4. patient is able to provide informed consent.

This study, sponsored by the National Institute of Mental Health, is being conducted in an attempt to identify genes associated with the development of agranulocytosis in patients treated with clozapine. We hope to develop a blood screening test that will predict which patients are at risk for developing the blood disorder before treatment with clozapine is started. Thus, patients who do not show specific genes would not have to undergo burdensome blood monitoring. Any interested patient should call us at 1-866-621-6898. Patient will have a single blood sample drawn.

This study is being conducted by
Anil Malhotra, MD
The Zucker Hillside Hospital
Psychiatry Research Department
Glen Oaks, NY 11004

For more information, contact us or call 718-470-8563.


Genetic Study of People with Schizophrenia or Bipolar Illness, and First-Degree RelativesPosted 28 November 2006

Contact: Dan Roche or Brad Folley, at or 860-545-7808

The Olin Neuropsychiatry Research Center at the Institute of Living at Hartford Hospital is starting a study of people with schizophrenia or bipolar illness and their first-degree relatives. Qualifying participants will be asked to come in on two separate days to participate in a brain imaging (MRI + EEG) and additional testing research project. Participants will be compensated $20 an hour. The study is open to adults aged 18-60 who have schizophrenia or bipolar disorder and to their relatives (parents, brothers, and/or sisters).


Brain Imaging Study of People with Schizophrenia and Their Family MembersPosted 7 November 2006

Contact: Dan Roche, at or 860-545-7808

The Olin Neuropsychiatry Research Center at the Institute of Living at Hartford Hospital (Hartford, CT) is starting a study of people with schizophrenia and their first-degree relatives (parents, brothers, and/or sisters). Qualifying participants will be asked to come in on two separate days to participate in a brain imaging (functional MRI) and memory testing research project. Participants will be compensated $20 an hour. The study is open to adults aged 18-60 who have schizophrenia and to the relatives mentioned above.


Antipsychotic-treated Schizophrenia Patients Posted 7 September 2006

Contact: Janet Munro at

A team of researchers from King's College London has recently created a new company focused on pharmacogenetic prediction tests in psychiatry. In order to rapidly progress our work, we are expanding our network of collaborators. We wish to team up with academic and clinical units internationally to obtain DNA and clinical data from patients with psychiatric disorders, for example, from well-characterized antipsychotic-treated schizophrenia patients. We are interested in collecting distinct cohorts from many different ethnicities, as the polymorphisms predicting response vary according to ethnic background.





Research Participants
Collaborators
Copyright © 2005- 2014 Schizophrenia Research Forum Privacy Policy Disclaimer Disclosure Copyright